Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anxiety Disorders | 21 | 2014 | 426 | 2.680 |
Why?
|
| Anti-Anxiety Agents | 7 | 2009 | 107 | 1.030 |
Why?
|
| Antipsychotic Agents | 5 | 2014 | 247 | 0.920 |
Why?
|
| Sphincter of Oddi Dysfunction | 5 | 2016 | 48 | 0.890 |
Why?
|
| Abdominal Pain | 4 | 2016 | 97 | 0.780 |
Why?
|
| Rivastigmine | 1 | 2021 | 6 | 0.770 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2021 | 58 | 0.740 |
Why?
|
| Apathy | 4 | 2021 | 28 | 0.700 |
Why?
|
| Antidepressive Agents | 5 | 2018 | 216 | 0.700 |
Why?
|
| Veterans | 4 | 2021 | 904 | 0.700 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2021 | 105 | 0.670 |
Why?
|
| Methylphenidate | 4 | 2021 | 97 | 0.650 |
Why?
|
| Cognitive Dysfunction | 1 | 2021 | 176 | 0.600 |
Why?
|
| Cholecystectomy | 3 | 2014 | 79 | 0.590 |
Why?
|
| Alzheimer Disease | 5 | 2021 | 565 | 0.520 |
Why?
|
| Mental Disorders | 5 | 2012 | 659 | 0.470 |
Why?
|
| Central Nervous System Stimulants | 3 | 2021 | 221 | 0.430 |
Why?
|
| Depressive Disorder | 5 | 2002 | 621 | 0.390 |
Why?
|
| Pain, Postoperative | 1 | 2014 | 214 | 0.390 |
Why?
|
| Double-Blind Method | 7 | 2021 | 1738 | 0.390 |
Why?
|
| Somatoform Disorders | 2 | 2005 | 35 | 0.380 |
Why?
|
| Risperidone | 2 | 2014 | 48 | 0.370 |
Why?
|
| Attention | 1 | 2013 | 225 | 0.370 |
Why?
|
| Suicidal Ideation | 1 | 2012 | 106 | 0.360 |
Why?
|
| Stress Disorders, Post-Traumatic | 4 | 2013 | 1506 | 0.360 |
Why?
|
| Panic Disorder | 7 | 1999 | 121 | 0.350 |
Why?
|
| Primary Health Care | 2 | 2013 | 703 | 0.340 |
Why?
|
| Adult | 31 | 2021 | 21403 | 0.340 |
Why?
|
| Pain | 2 | 2012 | 472 | 0.330 |
Why?
|
| Comorbidity | 11 | 2014 | 1426 | 0.320 |
Why?
|
| Sphincterotomy, Endoscopic | 3 | 2014 | 79 | 0.310 |
Why?
|
| Middle Aged | 25 | 2021 | 21147 | 0.310 |
Why?
|
| Sertraline | 2 | 2016 | 62 | 0.300 |
Why?
|
| Lisdexamfetamine Dimesylate | 2 | 2018 | 3 | 0.300 |
Why?
|
| Humans | 48 | 2021 | 68618 | 0.300 |
Why?
|
| Female | 34 | 2021 | 38074 | 0.290 |
Why?
|
| Treatment Outcome | 15 | 2018 | 7029 | 0.290 |
Why?
|
| Male | 30 | 2021 | 37321 | 0.280 |
Why?
|
| Phobic Disorders | 9 | 2009 | 227 | 0.270 |
Why?
|
| Aged | 19 | 2021 | 14862 | 0.250 |
Why?
|
| Psychiatric Status Rating Scales | 11 | 2014 | 782 | 0.230 |
Why?
|
| Depressive Disorder, Major | 3 | 2018 | 439 | 0.220 |
Why?
|
| Treatment Failure | 2 | 2021 | 216 | 0.220 |
Why?
|
| Dibenzothiazepines | 2 | 2014 | 15 | 0.210 |
Why?
|
| Psychotherapy | 1 | 2004 | 253 | 0.200 |
Why?
|
| Transdermal Patch | 1 | 2021 | 21 | 0.190 |
Why?
|
| Drug Therapy, Combination | 4 | 2018 | 649 | 0.170 |
Why?
|
| Duloxetine Hydrochloride | 2 | 2016 | 9 | 0.170 |
Why?
|
| Sclera | 2 | 1989 | 8 | 0.170 |
Why?
|
| Diagnosis, Differential | 5 | 2005 | 1140 | 0.150 |
Why?
|
| Complement System Proteins | 2 | 1989 | 135 | 0.150 |
Why?
|
| Pentagastrin | 1 | 1997 | 16 | 0.150 |
Why?
|
| Benzodiazepines | 2 | 2014 | 130 | 0.140 |
Why?
|
| Quetiapine Fumarate | 2 | 2014 | 20 | 0.140 |
Why?
|
| Neurotransmitter Agents | 1 | 1997 | 102 | 0.140 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1997 | 150 | 0.140 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2016 | 9 | 0.140 |
Why?
|
| Pituitary-Adrenal System | 1 | 1997 | 138 | 0.140 |
Why?
|
| Combined Modality Therapy | 3 | 2004 | 951 | 0.130 |
Why?
|
| Cross-Sectional Studies | 4 | 2020 | 2279 | 0.130 |
Why?
|
| Cohort Studies | 1 | 2021 | 2358 | 0.120 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2016 | 152 | 0.120 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 3 | 2014 | 348 | 0.120 |
Why?
|
| Aripiprazole | 1 | 2014 | 43 | 0.120 |
Why?
|
| Dementia | 1 | 1996 | 158 | 0.120 |
Why?
|
| Pilot Projects | 5 | 2016 | 1342 | 0.110 |
Why?
|
| Quinolones | 1 | 2014 | 60 | 0.110 |
Why?
|
| Severity of Illness Index | 3 | 2005 | 1851 | 0.110 |
Why?
|
| Piperazines | 1 | 2014 | 206 | 0.110 |
Why?
|
| Adolescent | 6 | 2018 | 8912 | 0.100 |
Why?
|
| Obsessive-Compulsive Disorder | 3 | 1998 | 88 | 0.100 |
Why?
|
| Disability Evaluation | 1 | 2014 | 298 | 0.100 |
Why?
|
| Placebos | 2 | 2005 | 195 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 931 | 0.100 |
Why?
|
| Area Under Curve | 1 | 2012 | 238 | 0.100 |
Why?
|
| Young Adult | 4 | 2018 | 5717 | 0.090 |
Why?
|
| Pain Measurement | 1 | 2012 | 328 | 0.090 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 517 | 0.090 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2016 | 257 | 0.090 |
Why?
|
| United States | 4 | 2018 | 7367 | 0.090 |
Why?
|
| Drug Administration Schedule | 3 | 2011 | 567 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 848 | 0.090 |
Why?
|
| Piracetam | 1 | 2009 | 10 | 0.090 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2000 | 54 | 0.090 |
Why?
|
| Motor Activity | 1 | 2013 | 621 | 0.090 |
Why?
|
| Psychometrics | 1 | 2012 | 514 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1753 | 0.070 |
Why?
|
| Manometry | 3 | 2014 | 276 | 0.070 |
Why?
|
| Sleep Deprivation | 2 | 1998 | 81 | 0.070 |
Why?
|
| Monoamine Oxidase Inhibitors | 2 | 1998 | 30 | 0.070 |
Why?
|
| Psychomotor Agitation | 2 | 1998 | 63 | 0.070 |
Why?
|
| Serotonin | 2 | 1998 | 144 | 0.070 |
Why?
|
| Prevalence | 4 | 2013 | 1619 | 0.070 |
Why?
|
| Terminology as Topic | 2 | 1998 | 141 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 1745 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2004 | 1330 | 0.070 |
Why?
|
| Serotonin Antagonists | 1 | 2005 | 31 | 0.070 |
Why?
|
| Sex Factors | 2 | 2002 | 1266 | 0.060 |
Why?
|
| Child | 3 | 2005 | 6405 | 0.060 |
Why?
|
| Remission Induction | 1 | 2004 | 111 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2018 | 186 | 0.060 |
Why?
|
| Child Abuse, Sexual | 1 | 2005 | 150 | 0.060 |
Why?
|
| Acute Disease | 1 | 2004 | 658 | 0.050 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2002 | 62 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2002 | 47 | 0.050 |
Why?
|
| Risk Factors | 1 | 2012 | 5731 | 0.050 |
Why?
|
| Age Factors | 3 | 1997 | 1864 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2002 | 301 | 0.050 |
Why?
|
| Fluvoxamine | 1 | 1999 | 22 | 0.040 |
Why?
|
| Bupropion | 1 | 2000 | 63 | 0.040 |
Why?
|
| Fluoxetine | 1 | 1999 | 40 | 0.040 |
Why?
|
| Crying | 1 | 1999 | 6 | 0.040 |
Why?
|
| Fenfluramine | 1 | 1998 | 6 | 0.040 |
Why?
|
| Maternal Behavior | 1 | 1999 | 29 | 0.040 |
Why?
|
| Serotonin Agents | 1 | 1998 | 13 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 1465 | 0.040 |
Why?
|
| Gyrus Cinguli | 1 | 1999 | 113 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 84 | 0.040 |
Why?
|
| Receptors, GABA-A | 1 | 1998 | 89 | 0.040 |
Why?
|
| Cholecystokinin | 1 | 1997 | 29 | 0.040 |
Why?
|
| Sodium Lactate | 1 | 1997 | 2 | 0.040 |
Why?
|
| Carbon Dioxide | 1 | 1997 | 78 | 0.030 |
Why?
|
| Caregivers | 1 | 2020 | 365 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2016 | 35 | 0.030 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 1996 | 45 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 1997 | 334 | 0.030 |
Why?
|
| Citalopram | 1 | 2016 | 30 | 0.030 |
Why?
|
| Venlafaxine Hydrochloride | 1 | 2016 | 42 | 0.030 |
Why?
|
| Norepinephrine | 1 | 1997 | 276 | 0.030 |
Why?
|
| Trazodone | 1 | 1996 | 5 | 0.030 |
Why?
|
| Cognition | 1 | 2020 | 513 | 0.030 |
Why?
|
| Ondansetron | 1 | 1996 | 13 | 0.030 |
Why?
|
| Delayed-Action Preparations | 2 | 2011 | 120 | 0.030 |
Why?
|
| Clozapine | 1 | 1996 | 46 | 0.030 |
Why?
|
| Models, Neurological | 1 | 1997 | 136 | 0.030 |
Why?
|
| Decision Trees | 1 | 1996 | 74 | 0.030 |
Why?
|
| Buspirone | 1 | 1996 | 36 | 0.030 |
Why?
|
| Carbamazepine | 1 | 1996 | 108 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1996 | 189 | 0.030 |
Why?
|
| Aggression | 1 | 1996 | 98 | 0.030 |
Why?
|
| Suicide, Attempted | 1 | 1996 | 72 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 4848 | 0.030 |
Why?
|
| Narcotics | 1 | 2014 | 65 | 0.030 |
Why?
|
| Mental Health Services | 1 | 1996 | 199 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 238 | 0.030 |
Why?
|
| Behavior Therapy | 1 | 1996 | 297 | 0.030 |
Why?
|
| Prefrontal Cortex | 1 | 1999 | 640 | 0.030 |
Why?
|
| Health Care Costs | 1 | 1996 | 346 | 0.030 |
Why?
|
| Models, Biological | 1 | 1997 | 981 | 0.030 |
Why?
|
| Pancreatitis | 1 | 2014 | 279 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 546 | 0.020 |
Why?
|
| Combat Disorders | 1 | 1992 | 102 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2013 | 307 | 0.020 |
Why?
|
| Health Status | 1 | 2014 | 429 | 0.020 |
Why?
|
| Health Surveys | 1 | 2013 | 489 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1040 | 0.020 |
Why?
|
| Anxiety | 1 | 2014 | 422 | 0.020 |
Why?
|
| Complement Hemolytic Activity Assay | 1 | 1989 | 4 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1999 | 2223 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 1989 | 134 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 4655 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 1989 | 282 | 0.020 |
Why?
|
| Hemolysis | 1 | 1988 | 39 | 0.020 |
Why?
|
| Pain Management | 1 | 2010 | 186 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2014 | 498 | 0.020 |
Why?
|
| Conjunctival Diseases | 1 | 1987 | 2 | 0.020 |
Why?
|
| Contact Lenses, Hydrophilic | 1 | 1987 | 5 | 0.020 |
Why?
|
| Teichoic Acids | 1 | 1987 | 7 | 0.020 |
Why?
|
| Corneal Diseases | 1 | 1987 | 12 | 0.020 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1987 | 19 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 1987 | 54 | 0.020 |
Why?
|
| Cornea | 1 | 1987 | 76 | 0.020 |
Why?
|
| Immunization | 1 | 1987 | 86 | 0.020 |
Why?
|
| Depression | 1 | 2014 | 943 | 0.020 |
Why?
|
| Antibodies | 1 | 1987 | 241 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 1987 | 175 | 0.020 |
Why?
|
| Research Design | 1 | 2010 | 729 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2014 | 3705 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 1998 | 1553 | 0.010 |
Why?
|
| Agoraphobia | 1 | 1999 | 59 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 1999 | 249 | 0.010 |
Why?
|
| Object Attachment | 1 | 1999 | 20 | 0.010 |
Why?
|
| Prolactin | 1 | 1998 | 61 | 0.010 |
Why?
|
| Mother-Child Relations | 1 | 1999 | 43 | 0.010 |
Why?
|
| Behavioral Symptoms | 1 | 1998 | 32 | 0.010 |
Why?
|
| Peripheral Nervous System | 1 | 1998 | 12 | 0.010 |
Why?
|
| Isoquinolines | 1 | 1998 | 37 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 1999 | 291 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 1999 | 291 | 0.010 |
Why?
|
| Heart Rate | 1 | 1999 | 568 | 0.010 |
Why?
|
| Blood Platelets | 1 | 1998 | 284 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1999 | 652 | 0.010 |
Why?
|
| Recurrence | 1 | 1996 | 948 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1999 | 1451 | 0.010 |
Why?
|
| Biomarkers | 1 | 1998 | 1593 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1999 | 2455 | 0.010 |
Why?
|
| Prisoners | 1 | 1992 | 50 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 1992 | 340 | 0.010 |
Why?
|
| Keratitis, Dendritic | 1 | 1987 | 1 | 0.000 |
Why?
|
| Keratoconjunctivitis | 1 | 1987 | 1 | 0.000 |
Why?
|
| Thimerosal | 1 | 1987 | 2 | 0.000 |
Why?
|
| Conjunctivitis, Allergic | 1 | 1987 | 2 | 0.000 |
Why?
|
| Injections, Intradermal | 1 | 1987 | 6 | 0.000 |
Why?
|
| Tears | 1 | 1987 | 9 | 0.000 |
Why?
|
| Conjunctiva | 1 | 1987 | 16 | 0.000 |
Why?
|
| Administration, Topical | 1 | 1987 | 111 | 0.000 |
Why?
|
| Injections | 1 | 1987 | 119 | 0.000 |
Why?
|
| Rabbits | 1 | 1987 | 509 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1987 | 481 | 0.000 |
Why?
|
| Substance-Related Disorders | 1 | 1992 | 1242 | 0.000 |
Why?
|
| Animals | 2 | 1992 | 20881 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 1992 | 7277 | 0.000 |
Why?
|
Brawman-Mintzer's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(212)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(20)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_